Moderna (NASDAQ:MRNA) Releases Earnings Results, Beats Expectations By $1.04 EPS

Moderna (NASDAQ:MRNA) announced its quarterly earnings results on Friday. The company reported ($3.40) earnings per share for the quarter, beating the consensus estimate of ($4.44) by $1.04, Briefing.com reports. The firm had revenue of $389.00 million during the quarter, compared to analyst estimates of $236.37 million. Moderna had a negative return on equity of 30.15% and a negative net margin of 145.16%.Moderna’s revenue for the quarter was up 260.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($2.52) EPS.

Here are the key takeaways from Moderna’s conference call:

• Q1 revenue of $400 million (driven by U.K. strategic partnerships) and a reiteration of up to 10% revenue growth for 2026, alongside a 26% year‑over‑year reduction in adjusted cash cost and ending cash/investments of $7.5 billion.
• Moderna recorded an $878 million cost‑of‑sales charge from a settlement and will make a lump sum payment of $950 million in Q3 2026, with a contingent additional payment of up to $1.3 billion if the Federal Circuit affirms liability under Section 1498; the company plans to appeal and views further payment as not probable.
• Regulatory and commercial momentum in Europe with EU approvals for mCOMBRIAX (the world’s first flu+COVID combo) and Spikevax, and a U.S. PDUFA date of August 5 for the seasonal flu vaccine mRNA‑1010, expected to help drive EU growth in 2027.
• Pipeline advancement with initiation of a phase III intismeran trial in high‑risk stage 1 non‑small cell lung cancer (including a monotherapy arm), an interim 5‑year update for intismeran in adjuvant melanoma due at ASCO, a fully enrolled phase III norovirus study and a pivotal readout for propionic acidemia expected in 2026.

Moderna Price Performance

MRNA traded down $0.57 during trading on Friday, reaching $45.37. The company’s stock had a trading volume of 10,215,449 shares, compared to its average volume of 9,738,576. The company has a market cap of $17.92 billion, a price-to-earnings ratio of -6.24 and a beta of 1.33. The firm has a fifty day simple moving average of $51.84 and a two-hundred day simple moving average of $39.29. Moderna has a 1 year low of $22.28 and a 1 year high of $59.55. The company has a quick ratio of 3.22, a current ratio of 3.29 and a debt-to-equity ratio of 0.07.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Q1 revenue sharply exceeded estimates — $389M (+~260% YoY) driven by strong international COVID‑19 vaccine sales, showing demand outside the U.S. and a meaningful top‑line rebound. Article Title
• Positive Sentiment: Pipeline and upcoming regulatory catalysts remain market drivers — the mRNA‑1010 seasonal flu PDUFA (Aug. 5) and advancing oncology programs give upside optionality beyond COVID vaccines. Article Title
• Neutral Sentiment: Company reiterated 2026 outlook (up to ~10% revenue growth) and signaled continued operating expense reductions excluding the non‑recurring settlement — suggests management expects sustainable margin improvements over time. Article Title
• Neutral Sentiment: Revenue concentration shifted heavily to ex‑U.S. markets (~80% of Q1 revenue), which helped the beat but increases sensitivity to international procurement cycles and government deals. Article Title
• Negative Sentiment: A $0.9B one‑time litigation settlement was recorded in Q1, producing a wider GAAP loss (GAAP EPS of $(3.40)) and negative gross/net margins — this sizable charge weighed on the earnings print despite the revenue beat. Article Title
• Negative Sentiment: Stock reaction was volatile — shares initially rallied on the revenue beat but later moved lower as investors digested the settlement, continued unprofitability, and reliance on a few government contracts. Article Title

Analyst Ratings Changes

Several brokerages have commented on MRNA. Barclays raised their price objective on Moderna from $25.00 to $48.00 and gave the company an “equal weight” rating in a report on Thursday, April 2nd. Royal Bank Of Canada increased their target price on Moderna from $25.00 to $30.00 and gave the company a “sector perform” rating in a research report on Tuesday, February 17th. TD Cowen reissued a “hold” rating on shares of Moderna in a research note on Thursday, January 29th. Wall Street Zen raised shares of Moderna from a “sell” rating to a “hold” rating in a report on Saturday, January 17th. Finally, Jefferies Financial Group set a $37.00 price objective on shares of Moderna and gave the stock a “hold” rating in a research report on Tuesday, March 3rd. Two equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and five have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Reduce” and an average price target of $34.07.

Insiders Place Their Bets

In other news, President Stephen Hoge sold 160,009 shares of the business’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $48.84, for a total transaction of $7,814,839.56. Following the transaction, the president owned 1,457,427 shares of the company’s stock, valued at approximately $71,180,734.68. The trade was a 9.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 10.80% of the company’s stock.

Institutional Trading of Moderna

Institutional investors and hedge funds have recently bought and sold shares of the stock. Alyeska Investment Group L.P. purchased a new stake in Moderna in the fourth quarter valued at approximately $95,209,000. Invesco Ltd. boosted its position in shares of Moderna by 15.7% during the third quarter. Invesco Ltd. now owns 8,216,163 shares of the company’s stock worth $212,223,000 after buying an additional 1,115,131 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Moderna by 123.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,788,951 shares of the company’s stock valued at $52,775,000 after buying an additional 987,312 shares in the last quarter. Worldquant Millennium Advisors LLC acquired a new stake in shares of Moderna in the second quarter valued at $23,192,000. Finally, Bank of America Corp DE raised its holdings in shares of Moderna by 84.3% in the 2nd quarter. Bank of America Corp DE now owns 1,779,309 shares of the company’s stock valued at $49,091,000 after buying an additional 813,974 shares during the period. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.